Moderna, Inc. 2021 Q1 - Results - Earnings Call Presentation

The following slide deck was published by Moderna, Inc. in conjunction with their 2021 Q1 earnings call.

Comments

[pauliel]

Impressive results. Clearly, Moderna believes there will be significant sales in 2022. 89% profit margin (I assume excluding SG&A) is phenomenal. CMV vaccine in P3. PCV, OX40L, VEGF in P2. Preparing for Phase 2 trialfor Zika; expected to begin in 2021. Phase 1 study of mRNA-1010 (Flu) expected to begin in 2021.
The only negative I saw in the presentation was the substantial increase in the number of diluted shares in the quarter (77MM). Presumably much of this is due to the exercise of option grants.

[Craig69]

We just have to hope that slippery Joe and his cohorts stay out of the way:-)

[ScienceMatters]

Interesting upcoming product lineup. Flu combo in 2023. A suite (CVM, PCV, EBV, Zika, VEGF, OX-402) planned in 5-10 yrs for a 10x impact (rev?). 2022 is for C19 variants and booster, much in APA already. Rev will be higher than 2021. I feel the story clear & buz plan aggressive but realistic. With this good visibility, rev and earning models can be updated. We will see updates soon from Street. When next two meds (likely CMV and flue combo) approved with others inline, the 5x MC is realistic in 2-3 yrs. I like the ER call and slides.

[BlackjackBill47]

Moderna is doing everything right!

[Chihawk Research]

Basically trading at 6 times this year's earnings and about 3.3x revenue with a scaled product and a year of Advanced Purchase Agreements. Right.

[Krypto]

Very impressive!

[jara-mill]

@Krypto - MOST impressive (as Darth Vader would say)

[ScienceMatters]

@Krypto indeed. Surprised to see this much APA for 2022 already. I like their “just do it” attitude, unlike NVAX just words.

[jara-mill]

@ScienceMatters - Moderna = NIKE; Novavax = Reebox